摘要
目的:观察地塞米松在肺纤维化过程中对胶原积聚的抑制作用,探讨地塞米松治疗肺纤维化的机理。方法:随机分为对照组、致伤组和治疗组,经气管内注射博莱霉素制备大鼠肺纤维化模型,通过腹腔注射地塞米松进行治疗,在肺纤维化形成过程的不同阶段测定肺组织胶原含量。结果:致伤组胶原含量在3、7、14、27d分别为:(26.59±0.62)mg,(34.24±0.48)mg,(37.06±0.19)mg,(31.79±0.11)mg,治疗组为:(24.99±0.05)mg,(31.65±0.63)mg,(30.56±0.59)mg,(28.38±0.19)mg,P<0.01。结论:地塞米松能够抑制肺纤维化因素导致的肺部正常组织的破坏及肺组织胶原的沉积,从而有效阻止肺纤维化的进展。
Objective:To investigate the inhibitory effects of dexamethasone on collagen accumulation and discuss the mechanism of dexamethasone in treatment of pulmonary fibrosis. Methods: The rats were divided into three groups:control group,injury group(IG) and dexamethasone group(DG).The model was made by a single intratracheal injection of bleomycin and treated with dexamethasone -via- celiac injection.In different stages,we detected the total lung collagen content. Results:At day 3,7,14,27,total lung collagen content in IG was: (26.59±0.62)mg,(34.24±0.48)mg,(37.06±0.19)mg,(31.79±0.11)mg. While in DG, they were: (24.99±0.05)mg, (31.65 ±0.63)mg,(30.56±0.59)mg and (28.38±0.19)mg ,respectively(-P-<0.01). Conclusion:Dexamethasone can inhibit the destruction of lung tissue structure and the accumulation of lung collagen. It can effectively prevent the development of pulmonary fibrosis.
出处
《西北国防医学杂志》
CAS
2005年第3期203-205,共3页
Medical Journal of National Defending Forces in Northwest China
基金
兰州军区医药卫生科研基金资助项目(LXH02-09)
关键词
肺纤维化
地塞米松
胶原
羟脯氨酸检测
Pulmonary fibrosis
Dexamethasone
Collagen
Hydroxyproline assay